Comparing SG&A Expenses: Merck & Co., Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Merck & Co., Inc. and Supernus Pharmaceuticals, Inc. from 2014 to 2023.

Merck & Co., Inc.: A Steady Giant

Merck's SG&A expenses have shown a consistent pattern, averaging around $10 billion annually. Despite a slight dip in 2020, likely due to global economic shifts, Merck's expenses rebounded, reflecting its robust market position.

Supernus Pharmaceuticals, Inc.: A Rising Contender

In contrast, Supernus Pharmaceuticals has experienced a remarkable growth trajectory. From 2014 to 2023, their SG&A expenses surged by over 400%, indicating aggressive expansion and increased market penetration.

This comparative analysis highlights the strategic financial maneuvers of these companies, offering insights into their operational priorities and market strategies.